New FDA Guidance Impacts the CAR-T Industry

New guidance, outlined by the FDA, affects all those in the CAR-T cell industry in a myriad of ways – from manufacturing to research.
In a contribution to GEN, SCTbio explained how these changes in the regulation will impact different stakeholders in the cell therapy sector.
To learn more visit HERE